What was the result of the AVERROES trial in comparing apixaban and aspirin in AF patients?
The AVERROES trial compared apixaban 5 mg bid with aspirin in AF patients who were not candidates for VKA and found that apixaban significantly reduced the risk of stroke or systemic embolism compared with aspirin (HR, 0.45; 95% CI, 0.32-0.62; P < .001). There was no significant difference in major bleeding (HR, 1.13; 95% CI, 0.74-1.75; P .57) between apixaban and aspirin.